Shares of Arcutis Biotherapeutics, Inc. (ARQT) have gained 34.5% over the past four weeks to close the last trading session at $11.51, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $18.43 indicates a potential upside of 60.1%.The average comprises seven short-term price targets ranging from a low of $11 to a high of $26, with a standard deviation of $4.50. While the lowest est ...